GC

DRUG4 trials

Sponsors

Hadassah Medical Organization, Peking Union Medical College Hospital, University Hospital, Bordeaux, NKMAX Co., Ltd.

Conditions

Bladder CarcinomaHealthyNephritis, LupusNon-small Cell Lung Cancer

Phase 1

Oral OKT3 in Combination With Beta-D-Glucosylceramide

Hadassah Medical OrganizationHealthy

Start: 2008-01-31End: 2008-06-30Target: 20Updated: 2009-02-04

A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment

NKMAX Co., Ltd.Non-small Cell Lung Cancer

Start: 2021-07-08End: 2023-05-26Target: 24Updated: 2021-07-21

Phase 2

Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis

Peking Union Medical College HospitalNephritis, Lupus

Start: 2012-07-31End: 2013-12-31Target: 130Updated: 2012-07-23

First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma

TerminatedNCT03324282

University Hospital, BordeauxBladder Carcinoma

Start: 2018-02-23End: 2022-01-14Updated: 2022-05-03

Related Papers

Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study

Journal for ImmunoTherapy of Cancer2024-03-017 citations

GCISAVE: A non-comparative randomized phase II study of combination of gemcitabine cisplatin (GCis) +/- avelumab (A) in 1st line treatment for locally advanced or metastatic urothelial bladder carcinoma (MUBC)—GETUG AFU V07.

Journal of Clinical Oncology2024-01-291 citations

The safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: Preclinical mouse model and phase I/IIa clinical study.

Journal of Clinical Oncology2023-06-01

Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve.

2020-06-013 citations